In addition, targeted therapies directed at BRAF, a gene mutated in 50% of melanomas and responsible for activating the MAPK/ERK-signaling pathway implicated in melanomagenesis [6], have demonstrated highly encouraging results in phase I, II, and III trials [3,4,7,8]. This evidence concerns the gene BRAF and melanoma.